The company is one of Romania’s largest drug exporters, with deliveries abroad of $26.9 million in 2013, up 34% against 2012.
“Antibiotice is present on 60 external markets. Last year’s increase came both amid the upward trend of exports of Nystatin for which Antibiotice became a global leader, and particularly on significant growth of exports of finite pharmaceutical products,” said Ioan Nani, general manager of Antibiotice.
According to Nani, the main pluses of exports are the higher profitability compared to that registered on the domestic market and the much lower duration of payments for deliveries. Another positive of exports is the lack of a clawback tax.
Antibiotice, like other Romanian producers, is seeking to strengthen its exports amid the increasingly more challenging domestic market.
For this year, Nani says the company plans to develop both on European Union markets, Australia and other emerging markets.
The manager added the development plan shows export revenue will double in the 2016-2020 period.
On the Romanian market, Antibiotice ranks 11th, with a market share of 2.5% (in the October 2012-September 2013 period), according with Cegedim Romania data.
The overall sales of Antibiotice, a company controlled by the Health Ministry, went up by 1.15% in the first nine months of 2013, to RON217 million (EUR49 million) mainly due to exports.
(English version by Catalina Apostoiu)